We apply our technology to identify new therapies for areas of high unmet medical need and orphan diseases including:
CNS disorders: Focus on Restoring Motor Function and Neuroprotection
Antibacterial Agents: Focus on Infections Caused by MultiDrug Resistant Pathogens
Talon Pharmaceuticals, through its Multiphore drug design platform, is focused on the discovery, development, and commercialization of medicines designed to save lives and improve patient quality of life. The single “magic bullet” approach to disease management has limitations often due to underlying multifactorial etiologies. For many diseases, concomitant pharmaceutical therapies are routinely employed to improve patient outcomes. The Multiphore approach combines two or more disease relevant pharmacophores into a single drug molecule that minimally targets two disease pathways. Our multi-target approach is designed to provide more effective medicines with improved patient compliance and lower cost.
We are applying the Multiphore technology to identify new therapies for rare disorders of the central nervous system and multidrug-resistant gram-negative bacterial infections. Our vision is to develop new products to treat both rare and challenging diseases and to provide patients with an improved quality of life while accelerating our discoveries from concept to the clinic as fast as possible.
Meet the management and advisors
Shawn Maddaford, PhD
Co-Founder, President and Chief Scientific Officer
David Vaughan, PhD
Co-founder and Chief Operating Officer
Jailall Ramnauth, PhD, MBA
Senior Vice President Discovery Chemistry
Talon Pharmaceuticals is developing several therapeutic agents to treat rare diseases of the CNS and Gram-negative antibiotic infections. All drug development candidates incorporate multiple mechanisms of action with suitable drug-like characteristics to support once or twice daily dosing.